Table 1.
Comparison of tumorigenic cell doses among distinct CRC phenotypic subpopulations
| Lin− phenotypic subpopulations* | Cell doses and tumor formation† |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10,000 | 8,000 | 6,000 | 5,000 | 4,000 | 2,000 | 1,000 | 800 | 400 | 200 | 150 | |
| CD44+ | 2/5‡ | — | — | — | — | — | — | — | — | — | — |
| CD44− | 0/5‡ | — | — | — | — | — | — | — | — | — | — |
| ESAhigh/CD44+ | — | — | — | 4/5 | — | 17/19¶ | 13/15 | 2/5 | 16/20 | 21/28 | — |
| All the rest (mainly CD44−/ESAlow) | 0/3§ | 0/5 | 0/5 | — | 0/5 | 1/30 | 0/19 | — | 0/10 | 0/20 | — |
| CD44+/CD166+ | — | — | — | — | — | — | 6/10 | — | — | — | — |
| CD44−/CD166+ | — | — | — | — | — | — | 1/10 | — | — | — | — |
| CD44+/CD166− | — | — | — | — | — | — | 0/7 | — | — | — | — |
| CD44−/CD166− | 0/10 | — | — | — | — | — | — | — | — | — | — |
| ESAhigh/CD166+ | — | — | — | — | 3/5‖ | — | — | — | — | — | — |
| All the rest (mainly ESAlow/CD166−) | — | — | — | — | 0/5‖ | — | — | — | — | — | — |
| ESAhigh/CD44+/CD166+ | — | — | — | — | — | — | — | — | — | — | 1/2‖ |
| ESAhigh/CD44+/CD166− | — | — | — | — | — | — | — | — | — | — | 0/2‖ |
| All the rest (mainly ESAlow/CD44−) | — | — | — | — | — | — | — | — | 0/2‖ | — | — |
*All populations are negative for nonepithelial lineage marker expression (Lin−).
†Cell dose, number of cells per injection; tumor formation, number of tumors formed/number of injections; tumor take was considered unsuccessful when no tumor mass was visible after 5 months follow-up. See also SI Tables 2 and 3.
‡Cell dose was 14,000.
§Cell dose was 12.000.
¶Five injections were performed with 2,500 cells and 14 with 2,000 cells.
‖Cells from primary tumor.